Book An Appointment

Dr. Sarada Pasangulapati

  • Home  | 
  • About Dr. Sarada Pasangulapati

Consultant Gastroenterologist, MBBS, MRCP (UK)

Banner Banner

About Dr. Sarada Pasangulapati

With experience of working and training in some of the most reputed centers such as Cambridge University Hospital, Dr. Sarada brings home some of the international practices in the management of various digestive and liver diseases. She is a JAG accredited endoscopist and is proficient in Upper GI Endoscopy, Colonoscopy and advanced endoscopic procedures such as Endoscopic ultrasound. She has dual accreditation in Gastroenterology and Hepatology and her specialist interests include management of various Liver and Pancreatic disorders.

Education and Experience

MBBS

MRCP (UK)

MRCP Gastroenterology

Conditions treated. Ulcer Disease, Acid Reflux / Heartburn, Nausea and Vomiting, Abdominal pain, bloating, Gallstones, Loose stools, constipation, Hemorrhoids / Piles, Anal fissure, Jaundice, Fatty Liver Disease, Cirrhosis, Pancreatitis

CCT – Gastroenterology, Hepatology, General Internal Medicine

FRCP (Glasgow)

Awards and Recognitions

  • Liver disease in Common Variable Immune Deficiency and non-invasive prediction of pathology, Sarada Pasangulapati, Huiqi Wang, Dinakantha Kumararatne, William JH Griffiths. Awarded top ranked poster at BASL annual conference August 2014

  • European Association for the Study of Liver Disease (EASL)

  • British Society of Gastroenterology (BSG)

  • British Association for the study of the liver (BASL).

  • Combined Phase 3, Double blind, Randomized, Placebo controlled Studies evaluating the efficacy and safety of Filgotinib in the induction and maintenance of remission in moderately to severely active Crohn's disease

  • A long term extension study to evaluate the safety of Filgotinib in subjects with Crohn's disease

  • Combined Phase 2b/3 double blind, randomized, placebo controlled studies evaluating the safety and efficacy of Filgotinib in the induction and maintenance of remission in subjects with moderately to severely active Ulcerative colitis

  • A long term extension study to evaluate the safety of Filgotinib in subjects with Ulcerative colitis

Book An Appointment